Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Publication | Closed Access

DOI

132

Citations

References

2018

Year

Tadeusz Robak, Jie Jin, Halyna Pylypenko, Gregor Verhoef, Noppadol Siritanaratkul, Johannes Drach, Markus Raderer, Juliana Pereira, Gayane Tumyan, Rumiko Okamoto,

The Lancet Oncology

Hematological MalignancyFrontline BortezomibLymphoid NeoplasiaTransplantationOncologyMantle Cell LymphomaMedicineHematologyImmunologyPathologyVersus RituximabRadiation OncologyImmunotherapyCell TransplantationCancer ResearchHealth Sciences